Cargando…
Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
BACKGROUND: The bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant gliom...
Autores principales: | Artene, Stefan-Alexandru, Turcu-Stiolica, Adina, Hartley, Richard, Ciurea, Marius Eugen, Daianu, Oana, Brindusa, Corina, Alexandru, Oana, Tataranu, Ligia Gabriela, Purcaru, Stefana Oana, Dricu, Anica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108618/ https://www.ncbi.nlm.nih.gov/pubmed/27877052 http://dx.doi.org/10.2147/OTT.S112842 |
Ejemplares similares
-
Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
por: Artene, Stefan-Alexandru, et al.
Publicado: (2018) -
Biobanking in a Constantly Developing Medical World
por: Artene, Stefan-Alexandru, et al.
Publicado: (2013) -
The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma
por: Alexandru, Oana, et al.
Publicado: (2018) -
Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines
por: Alexandru, Oana, et al.
Publicado: (2019) -
The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
por: Purcaru, Oana-Stefana, et al.
Publicado: (2021)